0
     

Report Added
Report already added
Netherlands Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

Netherlands Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

Summary

Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Dutch generics market had total revenues of $1.3 billion in 2021, representing a compound annual growth rate (CAGR) of 3.2% between 2016 and 2021.
- Market consumption volume increased with a CAGR of 2% between 2016 and 2021, to reach a total of 82.3 % in 2021.
- Over the past five years, the Dutch market recorded growth of 2.8%. Growth in the market has been driven by demographic trends alongside high adoption levels of generics.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the Netherlands
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the Netherlands
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands generics market with five year forecasts

Reasons to Buy

- What was the size of the Netherlands generics market by value in 2021?
- What will be the size of the Netherlands generics market in 2026?
- What factors are affecting the strength of competition in the Netherlands generics market?
- How has the market performed over the last five years?
- What are the main segments that make up the Netherlands's generics market?

Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How did the COVID-19 pandemic impact leading players?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Pfizer Inc.
8.4. Sanofi SA
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

List of Tables
Table 1: Netherlands generics market value: $ million, 2016-21
Table 2: Netherlands generics market volume: %, 2016-21
Table 3: Netherlands generics market geography segmentation: $ million, 2021
Table 4: Netherlands generics market value forecast: $ million, 2021-26
Table 5: Netherlands generics market volume forecast: %, 2021-26
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Viatris Inc.: key facts
Table 10: Viatris Inc.: Annual Financial Ratios
Table 11: Viatris Inc.: Key Employees
Table 12: Viatris Inc.: Key Employees Continued
Table 13: Pfizer Inc.: key facts
Table 14: Pfizer Inc.: Annual Financial Ratios
Table 15: Pfizer Inc.: Key Employees
Table 16: Pfizer Inc.: Key Employees Continued
Table 17: Sanofi SA: key facts
Table 18: Sanofi SA: Annual Financial Ratios
Table 19: Sanofi SA: Key Employees
Table 20: Sanofi SA: Key Employees Continued
Table 21: Netherlands size of population (million), 2017-21
Table 22: Netherlands gdp (constant 2005 prices, $ billion), 2017-21
Table 23: Netherlands gdp (current prices, $ billion), 2017-21
Table 24: Netherlands inflation, 2017-21
Table 25: Netherlands consumer price index (absolute), 2017-21
Table 26: Netherlands exchange rate, 2017-21

List of Figures
Figure 1: Netherlands generics market value: $ million, 2016-21
Figure 2: Netherlands generics market volume: %, 2016-21
Figure 3: Netherlands generics market geography segmentation: % share, by value, 2021
Figure 4: Netherlands generics market value forecast: $ million, 2021-26
Figure 5: Netherlands generics market volume forecast: %, 2021-26
Figure 6: Forces driving competition in the generics market in the Netherlands, 2021
Figure 7: Drivers of buyer power in the generics market in the Netherlands, 2021
Figure 8: Drivers of supplier power in the generics market in the Netherlands, 2021
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2021
Figure 10: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2021
Figure 11: Drivers of degree of rivalry in the generics market in the Netherlands, 2021

Report Title: Netherlands Generics Market Summary, Competitive Analysis and Forecast, 2017-2026


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM